Abstract 372P
Background
The therapeutic targets of pancreatic cancer (PC) are fewer. Cell-free DNA (cfDNA) has been a research hotspot in molecular tumour profiling. In advanced PC patients, malignant abdominal dropsy provides a wealth of tumour cells that can be investigated. The aim of this study is to investigate fusion landscape in advanced PC.
Methods
A multicenter study in China was initiated from Oct. 2016, and PC patients have been enrolled as of Apr. 2019. To determine the fusion frequency in PC, we analysed data from 536 clinical PC cases, each of which had results from next-generation sequencing (NGS)-based 808 genes panel assay, analogous to the index patient.
Results
Of this entire cohort, 24 patients (4.48%) were identified with fusions, including ARID1A-PIGV (1), HSD3BP4-HSD3B1 (1), CDKN2A-MTAP (1), PDE10A-BRAF (1), ETV6-NTRK3 (1), NOTCH1-RABL6 (1), ERRFI1-SLC25A33 (1),BRCA1-PTGES3L (1),MYCN-LINC00299 (1), CREBBP-CDIP1 (1), LPAR5-CHD4 (1), PMS2-ETV1 (1), RPTOR-ASPSCR1 (1), CHD2-SLCO3A1 (1), IDH2-SEMA4B (1), BAIAP2-RPTOR (1), CHEK1-OSBP (1), LRP1-KRT81 (1), TBX3-ACSS3 (1), RAB11FIP1-GPR124 (1), AXIN1-SNX29 (1), PPP2R1A-ZNF415 (1), BCL2L14-ETV6 (1) and BMX-NHS (1). BRAF, NTRK and BRCA1 fusions were seen in 12.50% (3/24) advanced Chinese pancreatic cancer fusion landscape patients. These three patients were diagnosed with pancreatic duct adenocarcinoma. For treatments, the BRAF fusion patient chose vemurafenib, another two patients chose chemotherapy, and this case of BRAF fusion patient responding to vemurafenib was actively being sought thru our database.
Conclusions
Advanced Chinese pancreatic cancer fusion landscape is rich, BRAF and NTRK fusions are rare but potentially druggable in TKIs. Detection of BRAF, NTRK, BRCA1, EGFR, ALK, ROS1, RET and ERBB2 fusions should be part of comprehensive profiling panels to determine TKIs and direct appropriate combination therapeutic strategies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Yiyu Shen.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
412P - The evaluation of chromosomal changes in patients with osteosarcoma
Presenter: Nargiza Karimova
Session: Poster display session
Resources:
Abstract
413P - The state of molecular biological markers in osteosarcoma
Presenter: Djamilya Polatova
Session: Poster display session
Resources:
Abstract
414P - Clinical profile of gastrointestinal stromal tumour in Yangon General Hospital
Presenter: Khin Mu
Session: Poster display session
Resources:
Abstract
415P - Adult soft tissue myoepithelial carcinoma: Treatment outcomes and efficacy of chemotherapy
Presenter: Florence Chamberlain
Session: Poster display session
Resources:
Abstract
417P - Clinicopathological profile and survival outcomes of sarcomas from a regional cancer centre in South India
Presenter: Divya Bharathi
Session: Poster display session
Resources:
Abstract
418P - Lessons learnt from treatment of foot sarcomas: Analysis from dedicated sarcoma clinic in North India
Presenter: Satyajit Pawar
Session: Poster display session
Resources:
Abstract
423P - Effectiveness of first-generation 5HT3 receptor antagonist plus dexamethasone plus aprepitant in controlling delayed chemotherapy-induced nausea and vomiting in patients with colorectal cancer: A propensity score-matched analysis
Presenter: Toshinobu Hayashi
Session: Poster display session
Resources:
Abstract
424P - Cancer worry, genetic knowledge, and attitudes towards NGS multigene panel testing among Korean breast cancer patients
Presenter: Ji Soo Park
Session: Poster display session
Resources:
Abstract
425P - Economic and safety evaluation of 5-HT3 recepter antagonist conversion from palonosetron to granisetron in highly and moderately emetogenic chemotherapy: A prospective study
Presenter: Keisuke Yamakita
Session: Poster display session
Resources:
Abstract
426P - Impaired quality of life of caregivers of patients with gastrointestinal cancer undergoing palliative chemotherapy
Presenter: Nobumichi Takeuchi
Session: Poster display session
Resources:
Abstract